Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 415, 116880
Abstract
No abstract availableKeywords
Funding Information
- Fritz og Ingrid Nilsens legat
- Hanne Linda Nakkestad at the Neurological Research Laboratory at Haukeland University Hospital
- SIMOA
- Bergen Research Foundation
- Haukeland University Hospital
- University of Bergen
- Centre for Clinical Treatment Research
- The Research Council of Norway (288164)
This publication has 8 references indexed in Scilit:
- Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancyNeurology Neuroimmunology & Neuroinflammation, 2020
- The natalizumab wearing-off effectNeurology, 2019
- Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision modelTherapeutic Advances in Neurological Disorders, 2014
- Multiple Sclerosis Symptom Recrudescence at the End of the Natalizumab Dosing CycleInternational Journal of MS Care, 2014
- Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational StudyPLOS ONE, 2012
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabAnnals of Neurology, 2010
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- The Fatigue Severity ScaleArchives of Neurology, 1989